Number needed to treat associated with ixekizumab and etanercept from UNCOVER-2 and UNCOVER-3 Phase III trials in the treatment of moderate-to-severe psoriasis

被引：0
|
作者：
Foster, S. [1 ]
Zhu, B. [1 ]
Burge, R. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2016年 / 136卷 / 05期
关键词：
D O I：
10.1016/j.jid.2016.02.177
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
150
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 50 条
  • [21] Efficacy of ixekizumab therapy: integrated analysis of 3 double-blind, controlled trials UNCOVER-1, UNCOVER-2, UNCOVER-3
    Papp, K.
    Leonardi, C.
    Blauvelt, A.
    Korman, N.
    Ohtsuki, M.
    Reich, K.
    Mallbris, L.
    Ball, S.
    Erickson, J.
    Griffiths, C. E.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (09) : S170 - S170
  • [22] Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials
    Craig Leonardi
    Kristian Reich
    Peter Foley
    Hideshi Torii
    Sascha Gerdes
    Lyn Guenther
    Melinda Gooderham
    Laura K. Ferris
    Christopher E. M. Griffiths
    Hany ElMaraghy
    Heidi Crane
    Himanshu Patel
    Russel Burge
    Gaia Gallo
    David Shrom
    Ann Leung
    Chen-Yen Lin
    Kim Papp
    Dermatology and Therapy, 2020, 10 : 431 - 447
  • [23] Safety profile of patients achieving complete or near complete resolution of moderate-to-severe psoriasis after 12 weeks of etanercept or ixekizu-mab: Integrated analyses from UNCOVER-2 and UNCOVER-3
    Blauvelt, Andrew
    Griffiths, Christopher E. M.
    Lebwohl, Mark
    Puig, Lluis
    Ball, Susan
    Warner, Margaret
    Zhang, Lu
    Dey, Debashish
    Mallbris, Lotus
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB269 - AB269
  • [24] Ixekizumab impact on health-related quality of life compared to etanercept and placebo: Results from UNCOVER-2, a phase 3 trial in patients with moderate-to-severe plaque psoriasis
    Reich, Kristian
    Toth, Darryl
    Nikai, Enkeleida
    Zhu, Baojin
    Carlier, Hilde
    Feldman, Steven
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S35 - S35
  • [25] Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3
    Kemeny, Lajos
    Berggren, Lovisa
    Dossenbach, Martin
    Dutronc, Yves
    Paul, Carle
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2019, 30 (01) : 19 - 26
  • [26] Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3
    van de Kerkhof, P.
    Guenther, L.
    Gottlieb, A. B.
    Sebastian, M.
    Wu, J. J.
    Foley, P.
    Morita, A.
    Goldblum, O.
    Zhang, L.
    Erickson, J.
    Ball, S.
    Rich, P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (03) : 477 - 482
  • [27] Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) (vol 18, pg 273, 2017)
    Blauvelt, Andrew
    Papp, Kim A.
    Griffiths, Christopher E. M.
    Puig, Luis
    Weisman, Jamie
    Dutronc, Yves
    Kerr, Lisa Farmer
    Ilo, Dapo
    Mallbris, Lotus
    Augustin, Matthias
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2018, 19 (03) : 457 - 457
  • [28] Ixekizumab treatment improves nail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized and controlled as well as open-label phases of UNCOVER-3
    van de Kerkhof, P.
    Guenther, L.
    Gottlieb, A.
    Sebastian, M.
    Wu, J.
    Foley, P.
    Morita, A.
    Goldblum, O.
    Zhang, L.
    Erickson, J.
    Ball, S.
    Rich, P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 69 - 69
  • [29] Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)
    Blauvelt, Andrew
    Gooderham, Melinda
    Iversen, Lars
    Ball, Susan
    Zhang, Lu
    Agada, Noah O.
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 77 (05) : 855 - 862
  • [30] Impact of ixekizumab treatment on scalp psoriasis: Results from the UNCOVER-2 trial
    Reich, Kristian
    Lebwohl, Mark
    Romiti, Ricardo
    Sofen, Howard
    Goldblum, Orin
    Kerr, Lisa
    Shrom, David
    Dennehy, Ellen
    Leonardi, Craig
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB253 - AB253
12345